Literature DB >> 3528289

Extravasation of intravascular fluid mediated by the systemic administration of recombinant interleukin 2.

M Rosenstein, S E Ettinghausen, S A Rosenberg.   

Abstract

Adoptive immunotherapy with lymphokine-activated killer cells and recombinant interleukin 2 (IL 2) can produce significant reduction of visceral metastases in tumor-bearing mice and, as shown recently, in humans with disseminated cancer. Because further dose escalations of IL 2 have been prevented by the development of a vascular leak syndrome (VLS) in both mice and humans, we investigated this VLS in mice undergoing the systemic administration of high-dose IL 2. A model for quantitating capillary permeability was used in which 125I-bovine serum albumin was injected i.v., and 2 hr later, tissues were counted in a gamma analyzer. A permeability index (PI) was calculated by dividing the mean counts per minute (cpm) of tissues from IL 2-treated mice by those from control animals. The injection of IL 2 produced increases in vascular permeability that were most pronounced in the thymus, spleen, lungs, liver, and kidneys (PI = 18.0, 10.0, 9.7, 6.7, and 6.3, respectively, on day 6). The development of the VLS was highly dependent on the number of days of IL 2 treatment (for example, the lungs contained 638, 1382, 3350, and 6187 cpm after 0, 1, 3, and 6 days of IL 2, respectively). Moreover, the degree of the VLS was directly related to the dose of IL 2 administered. Measurement of the wet and dry weights of lungs from IL 2-treated mice demonstrated that IL 2 produced a dramatic increase in their water weight (from 0.10 g at base line to 0.22 g after 200,000 U of IL 2 for 6 days). The injection of the IL 2 excipient failed to induce capillary leakage in tissues. Immunosuppression of mice by pretreatment irradiation (500 rad) or by injection of cyclophosphamide or by concurrent use of cortisone acetate markedly reduced or eliminated the development of the VLS. Similarly, the VLS was not observed in nude mice receiving IL 2. Thus, the administration of IL 2 produces a dose-limiting VLS that may be mediated, directly or indirectly, by host lymphoid elements.

Entities:  

Mesh:

Substances:

Year:  1986        PMID: 3528289

Source DB:  PubMed          Journal:  J Immunol        ISSN: 0022-1767            Impact factor:   5.422


  125 in total

1.  Kinetics of cellular infiltration and cytokine production during the efferent phase of a delayed-type hypersensitivity reaction.

Authors:  K L Buchanan; J W Murphy
Journal:  Immunology       Date:  1997-02       Impact factor: 7.397

2.  Potentiated lymphokine-activated killer cell activity generated by low-dose interleukin-2 and mismatched double-stranded RNA.

Authors:  H R Hubbell; G D Gibson; R D Bigler
Journal:  Cancer Immunol Immunother       Date:  1992       Impact factor: 6.968

3.  Mechanisms of edema formation in experimental autoimmune encephalomyelitis. The contribution of inflammatory cells.

Authors:  L Claudio; Y Kress; J Factor; C F Brosnan
Journal:  Am J Pathol       Date:  1990-11       Impact factor: 4.307

Review 4.  Generation of natural killer cells from hematopoietic stem cells in vitro for immunotherapy.

Authors:  Martha Luevano; Alejandro Madrigal; Aurore Saudemont
Journal:  Cell Mol Immunol       Date:  2012-06-18       Impact factor: 11.530

Review 5.  Adoptive T-Cell Immunotherapy.

Authors:  Stephen Gottschalk; Cliona M Rooney
Journal:  Curr Top Microbiol Immunol       Date:  2015       Impact factor: 4.291

Review 6.  [Systemic capillary leak syndrome causes a compartment syndrome of both lower legs and a forearm. A case report with a review of the literature].

Authors:  P Balcarek; K-H Frosch; M Quintel; K M Stürmer
Journal:  Unfallchirurg       Date:  2005-09       Impact factor: 1.000

Review 7.  Evolving principles in immunopathology: interleukin 10 and its relationship to Epstein-Barr virus protein BCRF1.

Authors:  K W Moore; F Rousset; J Banchereau
Journal:  Springer Semin Immunopathol       Date:  1991

8.  Pentoxifylline inhibits interleukin-2-induced toxicity in C57BL/6 mice but preserves antitumor efficacy.

Authors:  M J Edwards; B T Heniford; E A Klar; K W Doak; F N Miller
Journal:  J Clin Invest       Date:  1992-08       Impact factor: 14.808

Review 9.  Functions of γC cytokines in immune homeostasis: current and potential clinical applications.

Authors:  Willem W Overwijk; Kimberly S Schluns
Journal:  Clin Immunol       Date:  2009-05-09       Impact factor: 3.969

10.  Combination therapy with a synthetic peptide of C-reactive protein and interleukin 2: augmented survival and eradication of pulmonary metastases.

Authors:  B P Barna; M J Thomassen; M Maier; S V Medendorp; R R Tubbs; T Chiang; P Zhou; B Yen-Lieberman; S Singh-Burgess; S D Deodhar
Journal:  Cancer Immunol Immunother       Date:  1994-01       Impact factor: 6.968

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.